Skip to main content
. 2019 Sep 6;1(2):dlz042. doi: 10.1093/jacamr/dlz042

Table 1.

Clinical diagnoses of patients receiving meropenem

Diagnosis N (%)a
Respiratory tract infection 41 (37.3)
 bronchiectasis exacerbation 19 (17.3)
 ventilator-associated pneumonia 9 (8.2)
 hospital-acquired pneumonia 5 (4.5)
 community-acquired pneumonia 4 (3.6)
 cystic fibrosis exacerbation 4 (3.6)
Urinary tract infection 14 (12.7)
Intra-abdominal infection 12 (10.9)
Neutropenic sepsis 9 (8.2)
Post-neurosurgical CNS infection 6 (5.5)
Non-infectious diagnosisb 6 (5.5)
Other infectionc 8 (7.3)
CNS infection 4 (3.6)
Surgical site infection 4 (3.6)
Bacteraemia, unknown source 2 (1.8)
Osteomyelitis 2 (1.8)
Skin and soft tissue infection 2 (1.8)
a

n = 110 diagnoses as some patients had >1 diagnosis.

b

Methotrexate pneumonitis (n = 1); ischaemic bowel (n = 1); fever due to cancer (n = 3); and unknown but infection not proven (n = 1).

c

Line infection (n = 5); sepsis from unknown source (n = 1); infected spinal metalwork (n = 1); empyema and sub-phrenic collections (n = 1).